A Pilot Study of Intratumorally and Intraparenchymally Administered OS2966 Using Convection-enhanced Delivery in Patients With Recurrent/Progressive High-grade Glioma Undergoing a Clinically-indicated Surgical Resection
Latest Information Update: 22 Aug 2023
At a glance
- Drugs OS 2966 (Primary) ; Gadoteridol
- Indications Glioblastoma; Glioma
- Focus Adverse reactions; First in man
- Sponsors OncoSynergy
- 15 Aug 2023 Status changed from active, no longer recruiting to discontinued.
- 28 Nov 2022 Planned End Date changed from 1 Apr 2024 to 1 Oct 2025.
- 28 Nov 2022 Planned primary completion date changed from 1 Apr 2023 to 1 Oct 2023.